Mirtel

Quick links to important sections

Mirtel

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mirtel

What is Mirtel?

Mirtel is a prescription medication primarily used in the treatment of depressive disorders. It belongs to a group of medicines known as tetracyclic antidepressants. Unlike some other classes of antidepressants, it works by modulating specific chemical messengers in the brain that influence mood and emotional balance.

Mechanism of Action

The active component in Mirtel acts on the central nervous system to increase the levels of certain neurotransmitters, specifically noradrenaline and serotonin. These chemicals are naturally occurring substances in the brain that facilitate communication between nerve cells. By enhancing the activity of these neurotransmitters, the medication helps to alleviate the symptoms associated with depression.

Therapeutic Use

Mirtel is indicated for the treatment of major depressive episodes. Depressive disorders are characterized by persistent feelings of sadness, loss of interest in activities, and various physical and cognitive symptoms that interfere with daily functioning. The medication is intended to help stabilize mood and improve the overall emotional well-being of the patient over time.

Key Characteristics

  • Class: Tetracyclic antidepressant.
  • Form: Typically administered as oral tablets.
  • Primary Focus: Restoration of neurotransmitter balance to improve mood states.

What side effects are possible with Mirtel?

Possible Side Effects and Safety Information

The safety profile of Mirtazapine (Mirtel) is established by government regulatory bodies, detailing documented adverse reactions and necessary safety precautions.


Adverse Reaction Scope

Category Examples (as per regulatory documents)
Very Common (ge 10%) Somnolence (Drowsiness), Increased Appetite, Weight Gain, Dry Mouth.
Common (ge 1% to < 10%) Dizziness, Constipation, Asthenia (Weakness), Abnormal Dreams.
System-Organ Classes Nervous System Disorders, Metabolic and Nutritional Disorders, Gastrointestinal Disorders, and Blood and Lymphatic System Disorders.

Serious Adverse Reactions and Warnings

Serious adverse reactions are explicitly documented in regulatory sources:

  • Suicidal Thoughts and Behaviors (Boxed Warning): Risk is increased in adolescents and young adults (under 25) particularly during the initial phases of treatment or dose adjustment.
  • Agranulocytosis: A rare, potentially life-threatening blood disorder. Regulatory labels state that treatment must be discontinued immediately if symptoms of infection, such as fever or sore throat, occur.
  • Serotonin Syndrome: A serious condition linked to Mirtazapine, especially when used concurrently with other serotonergic medicines.
  • Cardiac Risks: Warnings include the risk of QT Prolongation (changes to the heart’s electrical activity).

Safety Considerations and Restrictions

Regulatory documents establish safety constraints for use:

  • Contraindications: Mirtazapine is contraindicated for use in patients taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of discontinuing an MAOI.
  • Special Populations: Caution is advised for use in elderly patients and those with renal or hepatic impairment, as drug clearance may be reduced. Mirtazapine is not approved for use in pediatric patients.
  • Discontinuation: Symptoms of a discontinuation syndrome (e.g., dizziness, anxiety) may occur upon abrupt cessation or dose reduction.

Connection to the Overall Safety Profile

The official safety information formally defines the spectrum of risks, from frequent, non-critical adverse events to rare, severe warnings highlighted by regulatory bodies. This structure establishes the factual limitations and necessary monitoring requirements for Mirtazapine as defined by governmental drug authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation describes the overdose profile for Mirtazapine (Mirtel) based on documented clinical manifestations and required emergency actions.

Documented Clinical Manifestations and Outcomes

Symptoms reported in association with overdose include disorientation, drowsiness, impaired memory, and tachycardia (rapid heart rate). The overdose may also manifest as CNS depression that can progress to coma, although this is rarer in single-agent ingestions.

Serious outcomes, including Serotonin Syndrome, are documented risks. Serotonin Syndrome is a potentially life-threatening reaction characterized by mental status changes, autonomic instability, and neuromuscular abnormalities, and can occur with Mirtel alone or in combination with other serotonergic agents. QT prolongation and Torsades de Pointes (TdP), serious cardiac complications, have also been reported, particularly in cases involving multiple drug overdoses.

Immediate Actions Required

Immediate medical attention must be sought for any suspected overdose, or if the user or caregiver observes signs of clinical worsening, unusual changes in behavior, or signs of severe toxicity like Serotonin Syndrome or seizures. Treatment is generally symptomatic and supportive, as official labeling states no specific antidote is known for Mirtazapine overdose. Management includes ensuring an adequate airway, oxygenation, ventilation, and continuous monitoring of vital signs and cardiac rhythm (ECG). Procedures such as activated charcoal or gastric lavage may be considered appropriate in specific management circumstances, as defined by medical professionals.

Therapeutic Uses of Mirtel

What Mirtel Treats: Main Uses and Benefits

Mirtel is commonly used across conditions presenting with episodic or recurrent symptom manifestations of Major Depressive Disorder (MDD) in adults. The medication is commonly used to help manage this condition.

Managing Symptom Clusters

Mirtel is relevant for easing symptomatic relief for the emotional and physical aspects of depression. It is applied across domains where additional symptomatic support is needed to address core symptoms such as pervasive low mood and hopelessness, as well as common co-occurring symptoms like insomnia and psychic anxiety. This action helps address symptom clusters that may become intense or disruptive.

The medication is applied in settings where patients experience significant symptom burden, including those with substantial decreased appetite and associated weight loss. This feature supports the patient during difficult episodes by easing discomfort related to appetite and weight, and may contribute to improved comfort during symptomatic periods.

Quick Fact: Relief for Sleep and Appetite Mirtel is applied when depression is characterized by prominent sleep disturbances and loss of appetite, providing supportive relief that helps patients cope more steadily with these physical manifestations.

Eligibility and Restrictions for Use

Eligibility Profile for Mirtel (Mirtazapine)

This section summarizes the official population eligibility and non-eligibility rules for Mirtel as documented by government regulatory authorities.

Classification Population Group Status in Regulatory Labeling
Contraindicated Patients with known hypersensitivity to mirtazapine or its excipients. Must not use
Patients taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of stopping one. Must not use
Approved Population Adults (18 years and older). Use indicated
Not Recommended Children and adolescents under 18 years. Not approved; use is not recommended
Conditional Use Patients with moderate to severe renal impairment. Caution required; clearance is reduced
Patients with hepatic impairment. Caution required; clearance is reduced
Older adults (Geriatric). Caution advised; greater risk for reduced clearance and side effects
Physiological State Pregnancy. Use only if clearly needed
Breastfeeding. Caution should be exercised

The most restrictive eligibility constraint is the absolute prohibition against use with MAOIs, including linezolid and intravenous methylene blue. Official labeling limits approved use to the adult population. For other groups, such as those with compromised liver or kidney function, use is considered conditional due to the drug's reduced clearance, requiring careful assessment.

What should I know about interactions with other medicines?

Mirtel Interactions with other medicines and products

Official regulatory documents categorize Mirtel's interactions based on metabolic clearance and additive pharmacodynamic effects.

Classification Interacting Medicines and Products Regulatory Restriction/Requirement
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue. Formal contraindication due to high risk of Serotonin Syndrome. A 14-day washout period is mandatory between stopping either substance before initiating the other.
Pharmacokinetic Interactions Strong CYP3A Inducers (e.g., Carbamazepine, Phenytoin) May decrease Mirtazapine plasma concentration; requires clinical monitoring.
Strong CYP3A Inhibitors (e.g., Ketoconazole, Cimetidine) May increase Mirtazapine plasma concentration; requires clinical monitoring.
Pharmacodynamic Reinforcement Other Serotonergic Drugs (e.g., Triptans, SSRIs, Lithium, St. John's wort) Documented risk of Serotonin Syndrome.
CNS Depressants (e.g., Alcohol, Benzodiazepines) Documented risk of additive CNS depression and impaired cognitive/motor function.
Drugs that Prolong QTc Interval Documented risk of QTc prolongation and ventricular arrhythmias.

Population-Specific Clearance Notes

The oral clearance of Mirtazapine is officially noted to be reduced in patients with hepatic impairment (approx. 30% decrease) and severe renal impairment (approx. 50% decrease), which impacts drug exposure and requires clinical consideration.

Mechanism of Action

How Mirtel Works


Dual Neurotransmitter Enhancement via \alpha2-Receptor Disinhibition

The primary mechanism involves the antagonism of presynaptic \mathbf\alpha2-adrenergic autoreceptors and heteroreceptors, which normally inhibit neurotransmitter release. By blocking this inhibitory "brake," Mirtel facilitates the disinhibition and resulting increased release of both Norepinephrine (NE) and Serotonin (5-HT) into the synaptic clefts of the central nervous system. This targeted action supports a more robust and sustained enhancement of dual neurotransmission, which modulates neural activity.


Selective Serotonin Signaling Through 5-HT1A Preference

Mirtel achieves functional selectivity by concurrently acting as an antagonist at the postsynaptic \mathbf5-HT2A and \mathbf5-HT2C receptors. This dual blockade strategically directs the newly released serotonin toward the \mathbf5-HT1A receptors, which are associated with specific physiological responses in this pathway. This precise channeling of the serotonin signal allows for a targeted pattern of signaling within the serotonergic system.


Central Histamine Blockade and Arousal System Dampening

The drug demonstrates high-affinity antagonism at the central Histamine \mathbfH1 receptors, which are key components of the brain's histaminergic arousal system. This strong receptor blockade causes an immediate and pronounced dampening of central histaminergic neurotransmission. This physiological change produces rapid-onset CNS depression** and sedation, often manifesting early in the course of treatment, separate from the slower neurotransmitter modulation effects.

Dosage and Administration Information

How to Use Mirtel (Mirtazapine): Official Administration Guidelines

This section describes the standardized protocol for administering Mirtazapine, outlining the established usage and administration patterns.


Administration Scope

Instruction Detail
Route of Administration The medication is taken orally.
Dosing Schedule (Adults) Treatment typically begins with an initial dose of 15 mg once daily. The standard maintenance range is 15 mg to 45 mg once daily, which is also the maximum recommended daily dose.
Frequency and Timing Mirtel is administered once daily, preferably as a single dose in the evening prior to sleep.
Food Relationship Administration can occur with or without food.
Preparation Requirements Film-coated tablets are swallowed whole with water. Orally Disintegrating Tablets (ODT) are placed on the tongue to dissolve and swallowed with saliva, without water.

Usage Patterns and Adjustments

Instruction Detail
Dose Titration Dose changes, if needed, should be conducted at intervals of no less than 1 to 2 weeks to properly evaluate response.
Population Adjustments Dose reduction may be necessary for patients with moderate to severe renal or hepatic impairment due to reduced clearance.
Duration of Use Continued use is generally advised for at least 6 months after symptoms are relieved to help ensure a sustained effect.

Procedural Structure

The official usage protocol defines a sequence starting with the once-daily oral administration of the initial dose, usually in the evening. This regimen establishes the fundamental pattern of use. Subsequent procedural steps involve gradual dose adjustment within the approved range over a period of weeks, guided by the patient's need and tolerance, and adherence to specific dose reductions for organ impairment when necessary. The medicine's use is structured as part of a long-term plan, often requiring continuation for several months.

Recent Clinical Evidence

Evidence for use in Major Depressive Disorder (MDD) – Acute Phase

Research examined the effect of Mirtel during periods of heightened symptom activity associated with Major Depressive Disorder (MDD) in adults. The core evidence relies on short-term Randomized Controlled Trials (RCTs), typically lasting 6 to 12 weeks. These studies compare the changes measured with Mirtel against those measured with an inactive substance (placebo) or other standard medicines. Researchers monitored symptom scores using standardized rating scales to track patient response and remission rates.

This high-quality evidence base is concentrated entirely on the acute treatment period, meaning follow-up durations were limited to only a few months. The results apply only to the specific populations studied, and evidence provides context but not individual predictions.


Evidence for Symptom Clusters Co-Occurring with MDD

Mirtel was studied for its impact on specific co-occurring symptoms. Research explored outcomes related to systemic or functional imbalance, including prominent sleep disturbances (insomnia), anxiety, and decreased appetite. Data on these specific changes, which reflect outcomes related to physical discomfort, are typically derived from sub-analyses of the general acute MDD studies.


Long-Term Studies and Durability of Measured Effects

Research also examined the durability of measured changes through maintenance studies. These trials monitored the risk of symptom relapse or recurrence over extended intervals in patients who had initially responded. A key research limitation is that long-term effects are not fully established because the body of formal, high-quality trials extending beyond one year is notably smaller, meaning there is limited information for long-term outcomes.


Evidence in Specific Patient Populations and Research Gaps

Mirtel was evaluated in some specific populations, such as older adults, through open-label trials or subgroup analyses. Conversely, data for certain groups remain insufficient, including children, adolescents, and patients with certain complex medical conditions. Comparative evidence is lacking for many head-to-head comparisons against newer antidepressants. The evidence quality varies across studies, and findings reflect the specific conditions under which they were conducted.

Key Studies & References

  1. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
  2. Mirtazapine: a review of its use in major depression (NCBI Bookshelf)
  3. Depression in adults: treatment and management (NICE guideline summary)

Frequently Asked Questions (FAQ)

Common questions about Mirtel (FAQ)


Q: How long does it usually take for Mirtel to start having an effect?

Studies and official information indicate that some effects, such as improvement in sleep, may be noticed early in the course of treatment. However, the full therapeutic benefit is often evaluated over a period of several weeks, with response typically assessed in the range of four to six weeks.


Q: Is Mirtel supposed to be taken long-term?

According to official product information, the medicine is generally advised to be continued for at least six months after symptoms have improved to help maintain a stable state. The long-term usefulness of the drug, which is supported by maintenance trials, is subject to periodic re-evaluation.


Q: Can Mirtel interact with cold or flu medicines?

Regulatory warnings advise caution with cold and flu medicines. Specifically, any medicine that increases serotonin activity (such as dextromethorphan, often found in cough syrups) or any medicine that causes CNS depression (sedation) may interact with Mirtel. These combinations may increase the risk of potential adverse effects or enhanced drowsiness.


Q: What types of food or drinks should be avoided when using Mirtel?

Official information states that Mirtel can be taken with or without food. However, regulatory documents caution against consuming Mirtel with alcohol, as this combination may significantly increase the risk of enhanced sedation and impaired mental or motor functions.


Q: Are there any herbal supplements that interact with Mirtel?

Yes, regulatory documents explicitly identify the herbal supplement St. John's wort (Hypericum perforatum) as one that should be avoided. This is because St. John's wort is a serotonergic agent, and combining it with Mirtel may increase the risk of a potential adverse reaction called Serotonin Syndrome.


Q: What happens if a dose of Mirtel is missed?

If a dose is missed, patients are generally advised by official sources to skip the missed dose entirely and take the next dose at the usual scheduled time. Taking a double dose to compensate for a missed dose is not recommended by official guidelines.


Q: Does Mirtel require a special diet?

No special diet is required with Mirtel; it can be taken with or without food. However, official information notes that increased appetite and weight gain are reported as very common side effects for some patients.


Q: Is Mirtel a controlled substance?

Mirtel (mirtazapine) is not currently classified as a federally controlled substance by major regulatory authorities like the U.S. Drug Enforcement Administration (DEA). It remains a prescription-only medication.


Q: What are the ingredients in Mirtel besides the main drug?

The active ingredient is mirtazapine. The tablets also contain several inactive ingredients (excipients) needed to form the pill, which can include common components like corn starch, lactose, and magnesium stearate. A full list is detailed in the official prescribing information.


Q: How quickly does Mirtel leave the body?

The drug is eliminated from the body with an average elimination half-life of approximately 20 to 40 hours in most adults. This means it takes up to 40 hours for the amount of the drug in the bloodstream to be reduced by half.


Q: Does Mirtel affect fertility?

Limited human data is available to definitively assess the risk to fertility. However, animal studies have shown a potential for adverse effects on reproduction at high doses. Based on this, official labeling includes information regarding the consideration of appropriate contraception methods.


Q: Can Mirtel be taken with pain relievers like ibuprofen?

Regulatory documents suggest caution when combining Mirtel with certain pain relievers, specifically Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen. This is because the combination may be associated with an increased risk of gastrointestinal bleeding.


Q: Are there known interactions between Mirtel and caffeine?

Official interaction information advises caution with Central Nervous System (CNS) Stimulants, a category that includes caffeine. Official interaction information describes caution with this class of compounds due to the potential for increased risk of behavioral disturbances.


Q: How is Mirtel eliminated from the body?

Mirtel is primarily eliminated after being extensively metabolized (broken down) in the liver. Most of the drug's breakdown products leave the body predominantly through the urine (about 75%) and, to a lesser extent, through the feces.


Q: Can Mirtel affect cholesterol levels?

Studies examining Mirtel's effect on blood lipids have been conducted. Some data indicate that the medicine may be associated with an increase in total cholesterol and a temporary rise in triglycerides in certain patients.


Q: What is the significance of the 'Black Box' warning (if applicable)?

The 'Boxed Warning' is the most serious safety warning required by the FDA for prescription drugs. For Mirtel, this warning highlights the risk of suicidal thoughts and behaviors in adolescents and young adults (under 25), especially when starting treatment or changing the dose.


Q: What is the typical timeframe for seeing the full benefit of Mirtel?

While initial improvement may be noted sooner, official patient information states that it usually takes between 4 to 6 weeks before the full therapeutic benefits of Mirtel are fully realized.


Q: Why is Mirtel sometimes taken in the evening?

Mirtel is often utilized as a single dose in the evening, usually before sleep. This timing is often utilized because the medicine commonly causes drowsiness (somnolence) and sedation, which are effects that may assist with sleep and minimize daytime impairment.


Q: What is the risk of overdose with Mirtel?

Taking more than the prescribed amount can lead to an overdose. Symptoms can include disorientation, severe drowsiness, confusion, and a fast heartbeat. Overdose is considered a medical emergency.


Q: Is Mirtel known to cause sweating?

Excessive sweating is not typically listed as a common side effect in major regulatory documents. This is because sweating can be a symptom of a condition called Serotonin Syndrome, which is a documented risk when Mirtel is used with other serotonergic medicines.


Q: Why do some people feel restless when starting Mirtel?

Official product information mentions that a feeling of inner restlessness and the inability to sit or stand still, known as akathisia, can occur as an infrequent side effect, particularly when treatment is started or the dose is adjusted.


Q: Is Mirtel available as a generic drug?

Yes, the active ingredient, mirtazapine, is available as a generic drug, in addition to its branded formulation, Mirtel.


Q: Can Mirtel affect blood pressure?

Mirtel has been associated with effects such as dizziness, and official information notes that some patients may experience low blood pressure upon standing (orthostatic hypotension). This is due to a drop in blood pressure when moving from a sitting or lying position.


Q: Does taking Mirtel affect mental clarity or focus?

Yes, regulatory documents list somnolence (drowsiness) and dizziness as common side effects, especially early in treatment. These effects can lead to impaired concentration and reduced mental clarity.


Q: Is it normal to feel a mild headache after starting Mirtel?

Yes, official regulatory documentation lists headache as a common side effect. This means it is an adverse reaction that may be experienced by some patients when first taking Mirtel.

How should Mirtel be stored and disposed of?

How to Store and Dispose of Mirtazapine (Mirtel)

Official Storage Requirements

Condition Regulatory Mandate
Temperature Store at controlled room temperature, between 20° and 25°C (68° and 77°F). Brief temperature excursions are permitted up to 30°C (86°F).
Protection Keep the product protected from light and moisture, and prevent it from freezing.
Packaging Keep the medicine in its original container, tightly closed, and keep it out of the sight and reach of children.
ODT Stability Orally disintegrating tablets must remain in the sealed blister pack until administration and must be used immediately upon removal.

Official Disposal Instructions

Disposal must follow any specific instructions provided on the drug's official labeling. The best method for discarding unused or expired Mirtazapine is via a drug take-back program. If a take-back program is unavailable, mix the tablets with an undesirable substance, such as dirt or used coffee grounds, and place the mixture into a sealed container before discarding it in the household trash. Mirtazapine is not classified as a medicine recommended for disposal by flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mirtel found in:

A-Z Index: